• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

byNeel MistryandTeddy Guo
June 29, 2022
in Chronic Disease, Hematology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Median event-free survival in the liso-cel group was significantly greater than in the standard-of-care group (10.1 months vs. 2.3 months).

2. Grade 3 or worse neutropenia was more common among the liso-cel group than control.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Primary refractory large B-cell lymphoma (LBCL) refers to disease relapse within 12 months of first-line immunochemotherapy treatment. Currently, outcomes with second-line approaches have been poor and there is a need for more effective therapies. CD-19 directed chimeric antigen receptor (CAR) T-cell therapy, such as lisocabtagene maraleucel (liso-cel), may help improve LBCL outcomes although evidence surrounding its effectiveness is lacking. This randomized controlled trial aimed to compare the safety and efficacy of liso-cel vs. standard-of-care therapy for treatment of refractory large B-cell lymphoma. The primary outcome was event-free survival while key secondary outcomes included complete response rate and overall survival. According to study results, the liso-cel groups reported significantly increased event-free survival compared to the standard-of-care group. Similar findings were seen with respect to overall and progression-free survival. This study was strengthened by a diverse sample of patients from different countries who were followed longitudinally for various clinical markers.

Click to read the study in The Lancet

Relevant Reading: Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

In-depth [randomized-controlled trial]: From Oct 23, 2018, and Dec 8, 2020, 232 patients were assessed for eligibility across 47 sites in the USA, Europe, and Japan. Included were patients aged 18-75 years with an Eastern Cooperative Oncology Group (ECOG) performance status score ≥1 and PET-confirmed LBCL. Altogether, 184 patients (92 each in liso-cel and standard-of-care group) were included in the analysis. The primary outcome of event-free survival at 6 months was significantly better in the liso-cel group (10.1 months, 95% confidence interval [CI] 6.1-not reached) vs. standard-of-care [SOC] group (2.3 months, 95% CI 2.2-4.3; stratified hazard ratio [sHR] 0.35, p<0.0001). Although common adverse events such as neutropenia (80% vs. 51%), anemia (49% vs. 49%), and thrombocytopenia (49% vs. 64%) were more frequent in the liso-cel group, overall serious treatment-related adverse events between both groups were comparable (48% each). Furthermore, one-treatment related death occurred which was in the SOC group. Findings from this study suggest the use of liso-cel in patients with refractory LBCL.

RELATED REPORTS

Efanesoctocog alfa is efficacious in treating severe hemophilia A

Ferric derisomaltose may reduce heart failure-related hospitalizations

Apixaban is associated with a lower risk of gastrointestinal bleeding than other direct oral anticoagulants

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: B-cell lymphomaCAR-T cell therapydiffuse large b cell lymphomaDiffuse large B-cell lymphoma (DLBCL)hematologyimmunochemotherapylarge b-cell lymphomalisocabtagene maraleucellymphomaneutropenia
Previous Post

Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency

Next Post

Radiofrequency thermal ablation superior to percutaneous ethanol injection in hepatocellular carcinoma [Classics Series]

RelatedReports

Nonleg venous thromboses associated with PE, longer ICU stay
Chronic Disease

Efanesoctocog alfa is efficacious in treating severe hemophilia A

February 2, 2023
No association found between length of storage for transfused red blood cells and patient mortality
Cardiology

Ferric derisomaltose may reduce heart failure-related hospitalizations

December 27, 2022
Blood type correlates with egg reserve in infertile women
Cardiology

Apixaban is associated with a lower risk of gastrointestinal bleeding than other direct oral anticoagulants

November 17, 2022
Quick Take: Left ventricular mechanical dispersion predicts arrhythmic risk in mitral valve prolapse
Cardiology

Apixaban is superior to rivaroxaban in patients with atrial fibrillation and valvular heart disease

October 31, 2022
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Radiofrequency thermal ablation superior to percutaneous ethanol injection in hepatocellular carcinoma [Classics Series]

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options